THU0082 Lung involvement in acpa positive subjects: a pilot study on the role of laboratory, functional and imaging markers

Background The ACPA-positive Rheumatoid Arthritis (RA) is a complex disease. Signs of immune activity against citrullinated proteins may be present years before the onset of clinical manifestations. Recent findings suggest that the lung may represent an early site of autoimmune-related injury in ACPA-positive patients without signs of arthritis. Objectives The purpose of the present study was to evaluate the presence of subclinical pulmonary abnormalities in ACPA-positive subjects without arthritis and in RA-patients through laboratory, functional and imaging markers. Methods Eleven ACPA-positive subjects without arthritis, 10 patients naive to therapy with early ACPA-positive RA ( Results The cohort consisted of 7 men and 23 women, mean age 48,93 (DS+/-12.1). PFTs resulted abnormal only in 2 patients. A DLCO reduction was observed in 54.5% of ACPA-positive subjects without RA, in 60% and in 55.6% of patients with early and established RA, respectively. In RA patients, an inverse correlation between disease duration and DLCO/Va (r=-0.50; p=0.03) was observed. The exercise tolerance at CPET was reduced in 54.5% of ACPA-positive subjects without RA, in 20% of patients with early RA and in 55.6% of those with established RA. Serum SP-D levels were higher in established RA (p=0.079), in ACPA-positive subjects and early RA than in healthy controls. ACPA levels positively correlated (r=0.45;p=0.01) with CPET parameters of ventilation inefficiency, suggesting a ventilation/perfusion mismatch. A negative correlation between ACPA and SP-D levels and CPET metabolic parameters was also observed. The presence of pulmonary nodules was the most common alteration founded at HRCT, equal to 28% in ACPA-positive subjects without arthritis, in 66% and 87% of patients with early and established RA, respectively. In the last group, all patients showed parenchymal abnormalities. There was also a significant (p=0.022) higher frequency of lung abnormalities in patients with established disease compared with the other two groups. Conclusions The early lung involvement in RA is often subclinical and baseline PFT9s are scarcely informative. Although preliminary, these findings suggest that DLCO, CPET parameters and SP-D can represent early markers of the subclinical lung injury. Furthermore, lung abnormalities detectable at HRCT seem to develop early in the course of the disease. However, additional studies are needed to clarify lung abnormalities in RA. Disclosure of Interest None declared